LSV Asset Management Sells 214,807 Shares of Baxter International Inc. $BAX

LSV Asset Management decreased its stake in shares of Baxter International Inc. (NYSE:BAX) by 4.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,307,693 shares of the medical instruments supplier’s stock after selling 214,807 shares during the quarter. LSV Asset Management’s holdings in Baxter International were worth $82,320,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cooke & Bieler LP boosted its holdings in shares of Baxter International by 25.7% during the 3rd quarter. Cooke & Bieler LP now owns 2,200,860 shares of the medical instruments supplier’s stock worth $50,114,000 after buying an additional 450,350 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Baxter International by 32.4% in the third quarter. Russell Investments Group Ltd. now owns 2,515,928 shares of the medical instruments supplier’s stock valued at $57,243,000 after acquiring an additional 615,100 shares in the last quarter. Greenhaven Associates Inc. acquired a new position in shares of Baxter International in the third quarter valued at about $143,186,000. DNB Asset Management AS grew its stake in shares of Baxter International by 304.7% in the third quarter. DNB Asset Management AS now owns 398,118 shares of the medical instruments supplier’s stock valued at $9,065,000 after acquiring an additional 299,750 shares in the last quarter. Finally, Stoneridge Investment Partners LLC acquired a new position in shares of Baxter International in the third quarter valued at about $2,128,000. Institutional investors own 90.19% of the company’s stock.

Baxter International News Summary

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Baxter’s shares are showing signs of a technical bottoming pattern after a steep healthcare-sector selloff, which could attract short-term buyers looking for a rebound. Baxter Stock Is Testing a Bottom After Healthcare Sector Decimation
• Positive Sentiment: Analysts at Zacks Research raised some near- and medium-term earnings estimates, including Q1 2028, Q4 2026, and Q2 2027, suggesting expectations for parts of Baxter’s earnings outlook are improving.
• Neutral Sentiment: Despite those higher estimates in a few periods, Zacks still maintains a “Strong Sell” rating on Baxter, so the broader analyst stance remains cautious.
• Negative Sentiment: Zacks also cut estimates for several key periods, including Q2 2026, Q3 2026, FY2026, Q3 2027, and FY2027, reinforcing concerns that earnings momentum may remain uneven.
• Negative Sentiment: The latest round of revisions keeps Baxter’s FY2026 forecast below the current consensus, which may weigh on sentiment if investors focus on softer near-term profitability.

Baxter International Trading Up 0.8%

BAX opened at $19.19 on Friday. Baxter International Inc. has a twelve month low of $15.73 and a twelve month high of $32.04. The company has a 50-day simple moving average of $17.48 and a 200 day simple moving average of $18.73. The company has a quick ratio of 1.23, a current ratio of 1.85 and a debt-to-equity ratio of 1.43. The stock has a market capitalization of $9.91 billion, a price-to-earnings ratio of -9.01, a P/E/G ratio of 3.09 and a beta of 0.62.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.05. Baxter International had a negative net margin of 9.70% and a positive return on equity of 16.15%. The business had revenue of $2.70 billion during the quarter, compared to analysts’ expectations of $2.62 billion. During the same quarter in the prior year, the business posted $0.62 earnings per share. Baxter International’s revenue was up 2.9% compared to the same quarter last year. Analysts predict that Baxter International Inc. will post 1.92 EPS for the current fiscal year.

Baxter International Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Friday, May 29th will be given a dividend of $0.01 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $0.04 annualized dividend and a yield of 0.2%. Baxter International’s dividend payout ratio is currently -1.88%.

Analysts Set New Price Targets

Several equities analysts recently commented on BAX shares. TD Cowen decreased their price target on shares of Baxter International from $22.00 to $20.00 in a research note on Friday, May 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Baxter International in a research note on Friday, May 15th. Stifel Nicolaus decreased their price target on shares of Baxter International from $20.00 to $19.00 in a research note on Friday, May 1st. Citigroup decreased their price target on shares of Baxter International from $21.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Finally, Wall Street Zen downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Baxter International has an average rating of “Reduce” and an average price target of $19.91.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.